The present invention involves a method of preparing Mirabilitum Praeparatum by pure strain fermentation and its application in treating infectious and inflammatory diseases, as well as health products and cosmetics. The method involves blending the ripe fruit (watermelon) of Citrullus lanatus (Thumb.) Matsumu.et Nakai with Mirabilite (Na.sub.2SO.sub.4.10H.sub.2O) according to a certain ratio as culture media and the pure strain Penicillium rubens as zymocyte, and then fermenting under a certain temperature. The Mirabilitum Praeparatum prepared by present method is different from that of prepared by traditional technology significantly, and the present invention possesses more advantages than the traditional method. The Mirabilitum Praeparatum prepared by present method, its extract shows powerful antibacterial and anti-inflammatory activities, which can be prepared into pharmaceutical preparations to treat infectious diseases of mucous membrane and skin, such as cavum oris ulcer, paradentosis, glossitis, rhinitis, laryngopharyngitis, dermatitis, otitis media, uterine cervicitis, kysthitis, and other health products and cosmetics.

The invention is a method for enhanced growth of mycelium in culture including the key steps of seed blend choice from among corn, rice, quinoa, chia, canihua, cumin and flax seed, germinating the seed blend prior to inoculating the mycelium starter, and conducting the mushroom cultivation with water and particular transmissions of sound and particularly colored light. Mushrooms grown by such a method not only mature in 13-15 days rather than 21 days, but have an enhanced nutritional and medicinal profile along with absence of unwanted organism contaminants whose unwanted overgrowth occurs during days 16-21 (or days 16-28) of typical mushroom culture.

The invention is a method for enhanced growth of mycelium in culture including the key steps of seed blend choice from among corn, rice, quinoa, chia, canihua, cumin and flax seed, germinating the seed blend prior to inoculating the mycelium starter, and conducting the mushroom cultivation with water and particular transmissions of sound and particularly colored light. Mushrooms grown by such a method not only mature in 13-15 days rather than 21 days, but have an enhanced nutritional and medicinal profile along with absence of unwanted organism contaminants whose unwanted overgrowth occurs during days 16-21 (or days 16-28) of typical mushroom culture.

An oral formulation as described herein can comprise pomegranate extract, panax ginseng extract, and c. sinensis, where each is present in an amount effective to counteract and/or prevent effects of aging in a subject when administered to the subject. The effects of aging can include age-related changes in gene expression.

An oral formulation as described herein can comprise pomegranate extract, panax ginseng extract, and c. sinensis, where each is present in an amount effective to counteract and/or prevent effects of aging in a subject when administered to the subject. The effects of aging can include age-related changes in gene expression.

Provided is a cyclic peptide derivative which is derived from Paecilomyces tenuipes having an astrocyte proliferative activity, or a salt thereof.

Provided is a cyclic peptide derivative which is derived from Paecilomyces tenuipes having an astrocyte proliferative activity, or a salt thereof.

New compositions and methods are provided for controlling a parasitic infection in a horse through administration of an effective amount of D. flagrans. In certain aspects, multiple, distinct strains of D. flagrans are administered. In additional aspects, the amount and treatment regimen of D. flagrans administered to a horse is based on one or more pre-identified characteristics of the horse, is combined with additional therapeutic agents for more comprehensive parasite control, or is accomplished via custom made, pre-measured daily dose packages. In another aspect, compositions and methods are provided that comprise combined use of 1) D. flagrans and 2) one or more insect growth regulators.

New compositions and methods are provided for controlling a parasitic infection in a horse through administration of an effective amount of D. flagrans. In certain aspects, multiple, distinct strains of D. flagrans are administered. In additional aspects, the amount and treatment regimen of D. flagrans administered to a horse is based on one or more pre-identified characteristics of the horse, is combined with additional therapeutic agents for more comprehensive parasite control, or is accomplished via custom made, pre-measured daily dose packages. In another aspect, compositions and methods are provided that comprise combined use of 1) D. flagrans and 2) one or more insect growth regulators.

New compositions and methods are provided for controlling a parasitic infection in a horse through administration of an effective amount of D. flagrans. In certain aspects, multiple, distinct strains of D. flagrans are administered. In additional aspects, the amount and treatment regimen of D. flagrans administered to a horse is based on one or more pre-identified characteristics of the horse, is combined with additional therapeutic agents for more comprehensive parasite control, or is accomplished via custom made, pre-measured daily dose packages. In another aspect, compositions and methods are provided that comprise combined use of 1) D. flagrans and 2) one or more insect growth regulators.